Mechanisms of resistance to ceftazidime/avibactam in mutants derived in vitro from Klebsiella pneumoniae producing OXA-48-like enzymes
| UDC.coleccion | Investigación | |
| UDC.departamento | Fisioterapia, Medicina e Ciencias Biomédicas | |
| UDC.endPage | 3272 | |
| UDC.grupoInv | Investigación en Microbiología (INIBIC) | |
| UDC.institutoCentro | INIBIC - Instituto de Investigacións Biomédicas de A Coruña | |
| UDC.issue | 12 | |
| UDC.journalTitle | Journal of Antimicrobial Chemotherapy | |
| UDC.startPage | 3265 | |
| UDC.volume | 80 | |
| dc.contributor.author | Blanco Martín, Tania | |
| dc.contributor.author | Guzmán-Puche, Julia | |
| dc.contributor.author | Hernández-García, Marta | |
| dc.contributor.author | Muñoz-Rosa, Montserrat | |
| dc.contributor.author | Elías-López, Cristina | |
| dc.contributor.author | Riazzo, Cristina | |
| dc.contributor.author | Torre-Cisneros, Julián | |
| dc.contributor.author | Arca-Suárez, Jorge | |
| dc.contributor.author | Causse, Manuel | |
| dc.contributor.author | Bou, Germán | |
| dc.contributor.author | Cantón, Rafael | |
| dc.contributor.author | Martínez-Martínez, Luis | |
| dc.date.accessioned | 2026-03-05T08:04:06Z | |
| dc.date.available | 2026-03-05T08:04:06Z | |
| dc.date.issued | 2025-09-29 | |
| dc.description.abstract | [Abstract] Objectives: To generate in vitro ceftazidime-avibactam-resistant mutants derived from Klebsiella pneumoniae producing OXA-48 or OXA-48 derivatives OXA-131 and OXA-232 carbapenemases, to define their antimicrobial susceptibility phenotype and to analyse mutations potentially involved in resistance to ceftazidime-avibactam. Methods: Mutants were obtained by plating overnight bacterial cultures on Mueller-Hinton agar plates containing increasing concentrations of ceftazidime-avibactam (0.5/4-32/4 mg/L). MICs were determined using Sensititre™ DKMNG panels. Whole-genome sequencing of 8 parental strains and 31 mutant derivatives was performed with Illumina. Results: All parental strains were susceptible to ceftazidime-avibactam (MIC ≤ 0.5/4-2/4 mg/L) and either susceptible or resistant to meropenem (MIC 0.5 to >16 mg/L) and imipenem (MIC ≤ 0.5 to >16 mg/L). MICs of ceftazidime-avibactam for the mutants increased up to 4 to >16 mg/L, while MICs of meropenem and imipenem for most mutants either increased up to >16 mg/L or remained unchanged. Whole-genome sequencing of the mutants identified alterations in genes coding for proteins related to AcrAB-TolC (AcrB, AcrR), PBPs (PBP2, PBP3), porins (OmpK36, EnvZ) or the stress or stringent responses (RseB, CpxA, SpoT). No mutations were detected in genes coding for OXA-48-like enzymes or other β-lactamases. Conclusions: Ceftazidime-avibactam can select in vitro mutants of OXA-48-like carbapenemase-producing K. pneumoniae resistant to this combination and, in some cases, also to carbapenems. No mutations related to ceftazidime-avibactam resistance were found in genes coding OXA-48-like enzymes, but they were detected in genes related to active efflux, PBPs, permeability or proteins of the stress and stringent responses. | |
| dc.description.sponsorship | This study was supported by Instituto de Salud Carlos III (projects PI20/01749 to L M-M and PI24/01449 to MH-G) and co-funded by the European Union. The research was also funded by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC; CB21/13/00049, CB21/13/00055, CB21/13/00084), integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–16 and funded by the Instituto de Salud Carlos III-General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) ‘A way of making Europe.’ T. B.-M. was supported by a grant from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) for a stay at the Service of Microbiology, University Hospital Ramón y Cajal, Madrid, Spain, and by the Río Hortega programme (Instituto de Salud Carlos III, CM23/00095). MH-G is supported by a postdoctoral contract by CIBERINFEC (CB21/13/00084). CE-L is supported by a predoctoral contract by CIBERINFEC (CB21/13/00049). | |
| dc.identifier.citation | Blanco-Martín T, Guzmán-Puche J, Hernández-García M, Muñoz-Rosa M, Elías-López C, Riazzo C, Torre-Cisneros J, Arca-Suárez J, Causse M, Bou G, Cantón R, Martínez-Martínez L. Mechanisms of resistance to ceftazidime/avibactam in mutants derived in vitro from Klebsiella pneumoniae producing OXA-48-like enzymes. J Antimicrob Chemother. 2025 Dec 2;80(12):3265-3272. | |
| dc.identifier.doi | 10.1093/JAC/DKAF360 | |
| dc.identifier.issn | 1460-2091 | |
| dc.identifier.uri | https://hdl.handle.net/2183/47586 | |
| dc.language.iso | eng | |
| dc.publisher | Oxford University Press | |
| dc.relation.uri | https://doi.org/10.1093/JAC/DKAF360 | |
| dc.rights | This is a pre-copyedited, author-produced version of an article accepted for publication in Journal of Antimicrobial Chemotherapy following peer review. The version of record is available online at Oxford Academic web. | |
| dc.rights.accessRights | embargoed access | |
| dc.subject | Anti-bacterial agents | |
| dc.subject | Azabicyclo compounds | |
| dc.subject | Ceftazidime | |
| dc.subject | Drug resistance, Bacterial | |
| dc.subject | Klebsiella pneumoniae | |
| dc.subject | beta-Lactamases | |
| dc.title | Mechanisms of resistance to ceftazidime/avibactam in mutants derived in vitro from Klebsiella pneumoniae producing OXA-48-like enzymes | |
| dc.type | journal article | |
| dc.type.hasVersion | AM | |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 909e08d1-6ed1-4b99-9e9e-c64eb72e7dea | |
| relation.isAuthorOfPublication.latestForDiscovery | 909e08d1-6ed1-4b99-9e9e-c64eb72e7dea |

